Scholarlink

<p>There is considerable variation among European, American, and Japanese guidelines regarding the management of Graves’ disease (GD) in early pregnancy. In contrast to European and the American Thyroid Association’s recommendations, the Japanese Thyroid Association includes potassium iodide (KI) as an alternative treatment option, reflecting long-standing clinical experience in iodine-sufficient populations. This review summarizes the historical background, pharmacologic mechanisms, and clinical evidence related to KI therapy in pregnant women with GD, with particular emphasis on data derived from Japanese clinical practice. The potential benefits, limitations, and safety concerns in regard to treatment with KI, including its rapid antithyroid effect and the risk of treatment escape, are discussed. The review also highlights areas of uncertainty and the need for careful patient selection and monitoring when treatment with KI is considered.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Iodide for the management of Graves’ disease in pregnancy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月25日

查看全文
  • Ai Yoshihara,
  • Jaeduk Yoshimura Noh,
  • Natsuko Watanabe,
  • Koichi Ito

摘要

There is considerable variation among European, American, and Japanese guidelines regarding the management of Graves’ disease (GD) in early pregnancy. In contrast to European and the American Thyroid Association’s recommendations, the Japanese Thyroid Association includes potassium iodide (KI) as an alternative treatment option, reflecting long-standing clinical experience in iodine-sufficient populations. This review summarizes the historical background, pharmacologic mechanisms, and clinical evidence related to KI therapy in pregnant women with GD, with particular emphasis on data derived from Japanese clinical practice. The potential benefits, limitations, and safety concerns in regard to treatment with KI, including its rapid antithyroid effect and the risk of treatment escape, are discussed. The review also highlights areas of uncertainty and the need for careful patient selection and monitoring when treatment with KI is considered.